You are here: Industry Insights > AstraZeneca

News List

EU committee recommends AstraZeneca’s Lynparza for breast cancer pharmaceutical-technology
March 05, 2019
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the use of Lynparza (olaparib) as monotherapy to treat breast cancer.
EMA panel backs approval of AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza in breast cancer firstwordpharma
March 04, 2019
AstraZeneca and partner Merck & Co. on Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of the PARP inhibitor Lynparza (olaparib) as monotherapy for the treatment of HER2-nega
EMA panel backs approval of AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza in breast cancer firstwordpharma
March 03, 2019
AstraZeneca and partner Merck & Co. on Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of the PARP inhibitor Lynparza (olaparib) as monotherapy for the treatment of HER2-nega
AstraZeneca announces its Brilinta reduced MACE in CAD and type 2 diabetes patients pharmaceutical-technology
February 26, 2019
Global pharmaceutical company AstraZeneca has announced its drug Brilinta (ticagrelor) in combination with aspirin has met its primary endpoint, a statistically significant reduction in major adverse cardiovascular events, in the Phase III THEMIS trial...
AstraZeneca rides high on sales rebound after cancer drugs, China once again pull through fiercepharma
February 24, 2019
It's confirmed: AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to cancer drugs Tagrisso and Lynparza—and once again, China.
AstraZeneca partners with NASSCOM expressbpd
February 22, 2019
The partnership between the two organisations will incubate start-ups in bringing innovative and frugal solutions that can help in the management of NCDs
Former AstraZeneca UK plant back up for sale, putting 270 jobs at risk fiercepharma
February 20, 2019
A CDMO that has made a habit of snapping up Big Pharma’s discarded manufacturing plants has put a former AstraZeneca plant into bankruptcy.
US and European regulatory agencies fast track AstraZeneca’s RSV drug pharmaceutical-technology
February 19, 2019
AstraZeneca and its division MedImmune have secured fast tract status for their respiratory syncytial virus (RSV) therapeutic, MEDI8897, from both the US and European regulatory authorities....
AstraZeneca licences Luye Pharma cholesterol drug in China pharmaceutical-technology
January 21, 2019
Luye Pharma has granted AstraZeneca’s Chinese division exclusive rights to promote its cholesterol medicine Xuezhikang Capsules in mainland China.
Luye Pharma strengthens commitment to cardiovascular therapeutic field biospectrumasia
January 17, 2019
Luye Pharma grants AstraZeneca exclusives rights to promote Xuezhikang Capsules in mainland China.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page